tradingkey.logo

Pacira Biosciences Inc

PCRX

21.631USD

-0.439-1.99%
Market hours ETQuotes delayed by 15 min
1.00BMarket Cap
LossP/E TTM

Pacira Biosciences Inc

21.631

-0.439-1.99%
More Details of Pacira Biosciences Inc Company
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Company Info
Ticker SymbolPCRX
Company namePacira Biosciences Inc
IPO dateFeb 03, 2011
CEOMr. Frank D. Lee
Number of employees790
Security typeOrdinary Share
Fiscal year-endFeb 03
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94005
Phone16502428052
Websitehttps://www.pacira.com/
Ticker SymbolPCRX
IPO dateFeb 03, 2011
CEOMr. Frank D. Lee
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.69K
-12.78%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
11.39K
+117.84%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Mr. Michael J. Yang
Mr. Michael J. Yang
Independent Director
Independent Director
--
--
Mr. Shawn M. Cross
Mr. Shawn M. Cross
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marcelo Bigal, M.D., Ph.D.
Dr. Marcelo Bigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Susan Mesco
Ms. Susan Mesco
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.69K
-12.78%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
11.39K
+117.84%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
EXPAREL
136.53M
0.00%
ZILRETTA
23.34M
0.00%
iovera
5.12M
0.00%
Bupivacaine liposome injectable suspension
2.60M
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
EXPAREL
136.53M
0.00%
ZILRETTA
23.34M
0.00%
iovera
5.12M
0.00%
Bupivacaine liposome injectable suspension
2.60M
0.00%
Shareholding Stats
Updated: Sun, Jul 13
Updated: Sun, Jul 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.61%
The Vanguard Group, Inc.
11.21%
D. E. Shaw & Co., L.P.
4.89%
Renaissance Technologies LLC
4.84%
Dimensional Fund Advisors, L.P.
4.43%
Other
60.03%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.61%
The Vanguard Group, Inc.
11.21%
D. E. Shaw & Co., L.P.
4.89%
Renaissance Technologies LLC
4.84%
Dimensional Fund Advisors, L.P.
4.43%
Other
60.03%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.40%
Hedge Fund
27.65%
Investment Advisor/Hedge Fund
25.71%
Research Firm
5.57%
Pension Fund
1.69%
Individual Investor
1.48%
Bank and Trust
1.05%
Sovereign Wealth Fund
0.32%
Holding Company
0.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
611
52.44M
113.25%
-16.62M
2025Q1
638
53.73M
116.03%
-16.46M
2024Q4
638
52.13M
112.66%
-21.91M
2024Q3
638
53.62M
116.22%
-11.06M
2024Q2
624
54.29M
116.65%
-6.10M
2024Q1
627
51.47M
110.71%
-7.99M
2023Q4
621
50.55M
108.88%
-6.71M
2023Q3
612
49.73M
107.18%
-6.05M
2023Q2
605
49.27M
107.14%
-5.45M
2023Q1
601
48.56M
105.72%
-5.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
6.77M
14.61%
-179.41K
-2.58%
Mar 31, 2025
The Vanguard Group, Inc.
5.19M
11.21%
-25.27K
-0.48%
Mar 31, 2025
D. E. Shaw & Co., L.P.
2.26M
4.89%
+6.43K
+0.29%
Mar 31, 2025
Renaissance Technologies LLC
2.24M
4.84%
+248.00K
+12.45%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.05M
4.43%
+217.22K
+11.86%
Mar 31, 2025
State Street Global Advisors (US)
1.98M
4.27%
+13.89K
+0.71%
Mar 31, 2025
DOMA Perpetual Capital Management, LLC
1.80M
3.9%
+56.22K
+3.22%
Mar 31, 2025
Balyasny Asset Management LP
1.57M
3.38%
+1.13M
+260.53%
Mar 31, 2025
Citadel Advisors LLC
1.33M
2.87%
+1.28M
+2700.84%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.31M
2.83%
+1.31M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Pacer US Small Cap Cash Cows Growth Leaders ETF
2.97%
SPDR S&P Pharmaceuticals ETF
2.6%
Invesco Pharmaceuticals ETF
2.5%
Simplify Health Care ETF
2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.85%
Invesco S&P SmallCap Health Care ETF
0.79%
VictoryShares Small Cap Free Cash Flow ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.56%
Royce Quant Small-Cap Quality Value ETF
0.53%
Distillate Small/Mid Cash Flow ETF
0.45%
View more
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion2.97%
SPDR S&P Pharmaceuticals ETF
Proportion2.6%
Invesco Pharmaceuticals ETF
Proportion2.5%
Simplify Health Care ETF
Proportion2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.85%
Invesco S&P SmallCap Health Care ETF
Proportion0.79%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.76%
iShares U.S. Pharmaceuticals ETF
Proportion0.56%
Royce Quant Small-Cap Quality Value ETF
Proportion0.53%
Distillate Small/Mid Cash Flow ETF
Proportion0.45%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI